Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aspire Biopharma Holdings ( (ASBP) ) has shared an update.
On January 26, 2026, Aspire Biopharma Holdings, Inc. entered into a Securities Purchase Agreement with certain investors under which it issued non-interest-bearing debentures with an 8% original issue discount, raising $2 million in gross proceeds and granting purchasers 790,000 common shares as incentive equity. The debentures, which are not convertible into common stock and mature by April 23, 2026 or sooner upon the company securing at least $8 million in new financing, were privately placed under a securities law exemption, and Aspire Biopharma plans to use the funds primarily to pay down existing debt and for working capital, signaling a near-term focus on balance-sheet strengthening and liquidity management.
More about Aspire Biopharma Holdings
Aspire Biopharma Holdings, Inc. operates in the biopharmaceutical sector, focusing on developing and commercializing healthcare-related products and technologies, with capital-raising activities that support its research, development, and operational needs in the life sciences market.
Average Trading Volume: 1,269,112
Technical Sentiment Signal: Sell
Current Market Cap: $5.5M
See more data about ASBP stock on TipRanks’ Stock Analysis page.